Assessed parameter | Interventions | P value | |
---|---|---|---|
Male | Female | ||
Prefrontal BDNF | Fluoxetine alone (SPS/SED-VEH vs SPS/SED-FLX) | 0.019 | 0.003 |
 | Exercise alone (SPS/SED-VEH vs SPS/EXC-VEH) | 0.000 | 0.001 |
 | Combination therapy (SPS/SED-VEH vs SPS/EXE-FLX) | 0.000 | 0.000 |
 | Combination therapy VS fluoxetine alone (SPS/SED-FLX vs SPS/EXE-FLX) | 0.001 | 0.565 |
 | Combination therapy VS exercise alone (SPS/EXC-VEH vs SPS/EXE-FLX) | 0.025 | 0.761 |
4th extinction | Fluoxetine alone (SPS/SED-VEH vs SPS/SED-FLX) | 0.000 | 0.05 |
 | Exercise alone (SPS/SED-VEH vs SPS/EXC-VEH) | 0.000 | 0.000 |
 | Combination therapy (SPS/SED-VEH vs SPS/EXE-FLX) | 0.000 | 0.000 |
 | Combination therapy VS fluoxetine alone (SPS/SED-FLX vs SPS/EXE-FLX) | 0.26 | 0.008 |
 | Combination therapy VS exercise alone (SPS/EXC-VEH vs SPS/EXE-FLX) | 0.56 | 0.51 |
Extinction index | Fluoxetine alone (SPS/SED-VEH vs SPS/SED-FLX) | 0.000 | 0.008 |
 | Exercise alone (SPS/SED-VEH vs SPS/EXC-VEH) | 0.000 | 0.001 |
 | Combination therapy (SPS/SED-VEH vs SPS/EXE-FLX) | 0.000 | 0.000 |
 | Combination therapy VS fluoxetine alone (SPS/SED-FLX vs SPS/EXE-FLX) | 0.34 | 0.054 |
 | combination therapy VS exercise alone (SPS/EXC-VEH vs SPS/EXE-FLX) | 0.75 | 0.13 |
OAT% | Fluoxetine alone (SPS/SED-VEH vs SPS/SED-FLX) | 0.000 | 0.823 |
 | Exercise alone (SPS/SED-VEH vs SPS/EXC-VEH) | 0.004 | 0.528 |
 | Combination therapy (SPS/SED-VEH vs SPS/EXE-FLX) | 0.001 | 0.000 |
 | Combination therapy VS fluoxetine alone (SPS/SED-FLX vs SPS/EXE-FLX) | 1 | − 0.004 |
 | Combination therapy VS exercise alone (SPS/EXC-VEH vs SPS/EXE-FLX) | 1 | − 0.019 |
OAE | Fluoxetine alone (SPS/SED-VEH vs SPS/SED-FLX) | 0.11 | 0.063 |
 | Exercise alone (SPS/SED-VEH vs SPS/EXC-VEH) | 0.001 | 0.0001 |
 | Combination therapy (SPS/SED-VEH vs SPS/EXE-FLX) | 0.000 | 0.000 |
 | Combination therapy VS fluoxetine alone (SPS/SED-FLX vs SPS/EXE-FLX) | 0.000 | 0.322 |
 | Combination therapy VS exercise alone (SPS/EXC-VEH vs SPS/EXE-FLX) | 0.83 | 0.965 |